Arkolith/Insider Trading/ELVN/Form 4

Heyman Richard A.

DirectorEnliven Therapeutics, Inc. (ELVN) · full profile →Form 4 · filed Jan 22, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$33K
Net Open-Market Flow
-$33K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 20, 2026Sell(S)512$26.46$14K25K
Jan 20, 2026Sell(S)718$26.96$19K24K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001584759-26-000007) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML